HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Professor Christoph Zielinski

Professor Zielinski is Director of the Comprehensive Cancer Center at Medical University Vienna and the General Hospital in Vienna, Austria, and is Scientific Director of the newly founded Vienna Cancer Center. Since 1999, he is President of the Central European Cooperative Oncology Group (www.cecog.org) which is conducting clinical trials and maor educational activities in 23 countries of Central and Southeastern Europe.

Professor Zielinski completed his medical training at the University Hospital Vienna and began his career with a position as a research fellow at the Cancer Research Center at Tufts University, Boston, USA. From 2004 to 2017 he was chairman of the Department of Medicine I and its Clinical Division of Oncology of the Medical University Vienna – General Hospital. His recent clinical research activities cover a wide range of cancer therapies, with particular focus on clinical trials, breast and lung cancer research and treatment and development of targeted drugs. He has published env. 600 original papers and reviews in peer-review journals and many books.

His h-Index is 59 and the citations of papers authored by him exceed 16.000.

Prof. Zielinski is Editor in Chief of the peer review open-access internet journal “ESMO Open – Cancer Horizons” which is one of two scientific journals of the European Society for Medical Oncology published by the BMJ group.

In 2013, Professor Zielinski received a “Dr. h.c.” degree from Titu Maiorescu University in Bucharest.

Professor Zielinski is a member of the European Society for Medical Oncology (ESMO) where he served on the Executive Board and as Chair of the Fellowships and Awards Committee from 2014-2017. He was Local Officer of the ESMO Annual Meeting 2012 and the ECC Meeting 2015. Prof. Zielinski is a Honorary Member of the Polish Society for Clinical Oncology and also member of the Austrian Society for Hematology and Oncology, the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the Chinese Society for Clinical Oncology (CSCO).

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551